Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses
- 1 May 1995
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 39 (5) , 1082-1086
- https://doi.org/10.1128/aac.39.5.1082
Abstract
The pharmacokinetics and suction-induced blister fluid penetration of cefdinir following single oral administrations of 200, 300, 400, and 600 mg were studied in 16 healthy young male volunteers according to a Latin square design. Plasma, blister, and urine samples were assayed by high-pressure liquid chromatography. We observed a nonlinear relationship (P = 0.02) between the dose and the maximum concentration in plasma as well as between the dose and the area under the concentration-time curve (AUC) in plasma (P < 0.001), which may be indicative of a limited absorption process. This resulted in a lower AUC value than expected as well as a smaller fraction of cefdinir excreted unchanged at a dose of 600 mg. Renal clearance decreased with increasing doses (P < 0.006; analysis of variance with the Latin square design and Games-Howell procedure). Maximal cefdinir concentrations in blister fluid were delayed compared with concentrations in plasma. Blister fluid penetration measured by the ratio of the AUC in blister fluid to the AUC in plasma was extensive (92.4 to 108.4%). Cefdinir concentrations in blister fluid remained equal to or higher than the concentrations in plasma from 6 to 12 h following cefdinir administration. On the basis of the concentrations in blister fluid and the in vitro MIC data, we estimated that cefdinir at 200 to 400 mg administered twice daily would be adequate to treat uncomplicated skin infections caused by Streptococcus pyogenes. Seven volunteers experienced episodes of light-to-moderate diarrhea. These adverse events occurred irrespective of dose.Keywords
This publication has 12 references indexed in Scilit:
- Impairment of cefdinir absorption by iron ionClinical Pharmacology & Therapeutics, 1993
- Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogensEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393): A novel orally administered cephalosporinDiagnostic Microbiology and Infectious Disease, 1991
- The in-vitro activity of cefdinir (FK482), a new oral cephalosporinJournal of Antimicrobial Chemotherapy, 1991
- Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteersAntimicrobial Agents and Chemotherapy, 1990
- Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.1990
- Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporinAntimicrobial Agents and Chemotherapy, 1989
- In vitro antibacterial activity of FK482, a new orally active cephalosporin.The Journal of Antibiotics, 1988
- FK 482, a new orally active cephalosporin. Synthesis and biological properties.The Journal of Antibiotics, 1988
- Pharmacokinetics of Tissue Penetration of AntibioticsClinical Infectious Diseases, 1981